title: A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
abstract: BACKGROUND
  The objective of this study was to estimate antitumor activity and toxicity of weekly docetaxel and gemcitabine as second-line chemotherapy for patients with recurrent uterine carcinosarcoma.
  
  
  METHODS
  Patients with recurrent carcinosarcoma of the uterus who had failed one regimen of chemotherapy, had a Gynecologic Oncology Group (GOG) performance status of 0-2 and had measurable disease were included. Treatment consisted of gemcitabine 600 mg/m(2) and docetaxel 35 mg/m(2) intravenously on days 1, 8 and 15 of a 28-day cycle until disease progression or intolerable adverse effects. This study employed an optimal but flexible two-stage design with an early stopping rule. If more than 3 out of 22-24 or more than 4 out of 25-29 patients responded, accrual to the second stage was to be initiated.
  
  
  RESULTS
  Twenty-eight patients were enlisted. Three patients were not eligible after pathology review. One patient was never treated. Twenty-four patients were evaluable. Nine patients had previous radiation therapy. There were no complete responses. Partial responses were seen in two patients (8.3%), stable disease in eight (33.3%) and progressive disease in 12 patients (50%). Two patients were not evaluable (8.3%). The median progression-free survival was 1.8 months. The median survival was 4.9 months. The treatment caused myelosuppression, mainly neutropenia, but also thrombocytopenia and anemia. Dose modifications became necessary in the majority of patients. In five patients, treatment was discontinued due to toxicity.
  
  
  CONCLUSIONS
  This regimen of docetaxel and gemcitabine is not active in patients with recurrent carcinosarcoma of the uterus as second-line chemotherapy.
authors.affiliation: Carolinas Medical Center, North East Oncology Associates, 100 Medical Park Drive, Concord, NC 28025, USA. brigitte.miller@carolinashealthcare.org
authors.forename: Brigitte E
authors.initials: BE
authors.lastname: Miller
authors.forename: John A
authors.initials: JA
authors.lastname: Blessing
authors.forename: Frederick B
authors.initials: FB
authors.lastname: Stehman
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shahin
authors.forename: S Diane
authors.initials: SD
authors.lastname: Yamada
authors.forename: Angeles Alvarez
authors.initials: AA
authors.lastname: Secord
authors.forename: David P
authors.initials: DP
authors.lastname: Warshal
authors.forename: Ovadia
authors.initials: O
authors.lastname: Abulafia
authors.forename: William E
authors.initials: WE
authors.lastname: Richards
authors.forename: Linda
authors.initials: L
authors.lastname: Van Le
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002296:Carcinosarcoma / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D014594:Uterine Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine